101.87
-0.04 (-0.03%)
| Previous Close | 101.90 |
| Open | 101.81 |
| Volume | 270,214 |
| Avg. Volume (3M) | 5,293,265 |
| Market Cap | 19,330,494,464 |
| Price / Earnings (Forward) | 185.19 |
| Price / Sales | 6.23 |
| Price / Book | 7.77 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Profit Margin | -36.06% |
| Operating Margin (TTM) | -11.53% |
| Diluted EPS (TTM) | -5.53 |
| Quarterly Revenue Growth (YOY) | 10.90% |
| Total Debt/Equity (MRQ) | 105.93% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | 323.66 M |
| Levered Free Cash Flow (TTM) | 163.08 M |
| Return on Assets (TTM) | -1.83% |
| Return on Equity (TTM) | -36.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Exact Sciences Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.38 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 98.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Mizuho, 3.08%) | Hold |
| 105.00 (Evercore ISI Group, 3.08%) | Hold | |
| 105.00 (Stifel, 3.08%) | Hold | |
| 105.00 (Canaccord Genuity, 3.08%) | Hold | |
| 105.00 (Jefferies, 3.08%) | Hold | |
| 105.00 (Wells Fargo, 3.08%) | Hold | |
| 105.00 (Barclays, 3.08%) | Hold | |
| Median | 105.00 (3.08%) | |
| Low | 75.00 (Benchmark, -26.37%) | Buy |
| 75.00 (Guggenheim, -26.37%) | Buy | |
| Average | 94.46 (-7.27%) | |
| Total | 6 Buy, 7 Hold | |
| Avg. Price @ Call | 86.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 20 Jan 2026 | 105.00 (3.08%) | Hold | 102.35 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (3.08%) | Hold | 101.61 |
| Stifel | 28 Nov 2025 | 105.00 (3.08%) | Hold | 101.29 |
| 04 Nov 2025 | 80.00 (-21.46%) | Buy | 69.59 | |
| Canaccord Genuity | 25 Nov 2025 | 105.00 (3.08%) | Hold | 101.13 |
| Jefferies | 24 Nov 2025 | 105.00 (3.08%) | Hold | 101.01 |
| Barclays | 21 Nov 2025 | 105.00 (3.08%) | Hold | 100.90 |
| 04 Nov 2025 | 77.00 (-24.41%) | Buy | 69.59 | |
| Wells Fargo | 21 Nov 2025 | 105.00 (3.08%) | Hold | 100.90 |
| 05 Nov 2025 | 85.00 (-16.56%) | Buy | 69.63 | |
| Piper Sandler | 11 Nov 2025 | 80.00 (-21.46%) | Buy | 67.50 |
| BTIG | 04 Nov 2025 | 85.00 (-16.56%) | Buy | 69.59 |
| Baird | 04 Nov 2025 | 88.00 (-13.61%) | Buy | 69.59 |
| Benchmark | 04 Nov 2025 | 75.00 (-26.37%) | Buy | 69.59 |
| Guggenheim | 04 Nov 2025 | 75.00 (-26.37%) | Buy | 69.59 |
| TD Cowen | 04 Nov 2025 | 90.00 (-11.65%) | Buy | 69.59 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |